Photodynamic therapy in the treatment of breast cance;Terapia fotodynamiczna w leczeniu raka piersi

Polski Merkuriusz Lekarski

Volumn 33, Issue 195, 2012, Pages 173-175

  PŁonka, Justyna ^a   Latocha, MaŁgorzata ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Breast cancer; Photodynamic therapy

Indexed keywords

CASPASE; PHOTOSENSITIZING AGENT;

BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; REVIEW;

BREAST NEOPLASMS; CASPASES; FEMALE; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84871870077     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Akens M.K., Yee A.J., Wilson B.C. et al.: Photodynamic therapy of vertebral metastases: evaluating tumor-to-neural tissue uptake of BPD-MA and ALA-PpIX in a murine model of metastatic human breast carcinoma. Photochem. Photobiol., 2007; 83; 1034-1039.
2. Akens M.K., Hardisty M.R., Wilson B.C. et al.: Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin). Breast Cancer Res. Treat., 2010; 119; 325-333.
3. Allison R., Mang T., Hewson G. et al.: Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer, 2001; 91; 1-8.
4. Allison R.R., Sibata C., Downie G.H. et al.: Photodynamic therapy of the intact breast. Photodiag. Photodyn. Ther., 2006; 3; 139-146.
5. Boyle P., Levin B.: World Cancer Report 2008. Lyon, International Agency for Research on Cancer, 2008; 296-301; 412-417.
6. Burch S., Bisland S.K., Bogaards A. et al.: Photodynamic therapy for the treatment of vertebral metastases in a rat model of human breast carcinoma. J. Orthop. Res., 2005; 23; 995-1003.
7. Buytaert E., Dewaele M., Agostinis P.: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta, 2007; 1776; 86-107.
8. Castano A.P., Demidova T.N., Hamblin M.R.: Mechanisms in photodynamic therapy. Part three: Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiag. Photodyn. Ther., 2005; 2; 91-106.
9. Crescenzi E., Varriale L., Iovino M. et al.: Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol. Cancer Ther., 2004; 3; 5; 537-544.
10. Cuenca R.E., Allison R.R., Sibata C. et al.: Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann. Surg. Oncol., 2004; 11; 3; 322-327.
11. Di Sibio G., French S.W.: Metastatic patterns of cancers. Results from a large autopsy study. Arch. Pathol. Lab. Med., 2008; 132; 931-939.
12. Li B., Chu X., Gao M. et al.: Apoptotic mechanism of MCF-7 breast cells in vivo and in vitro induced by photodynamic therapy with C-phycocyanin. Acta. Biochim. Biophys. Sin., 2010; 42; 1; 80-89.
13. Marchal S., Francois A., Dumas D. et al.: Relationship between subcellular localization of Foscan® and caspase activation in photosensitized MCF-7 cells. Br. J. Cancer, 2007; 96; 944-951.
14. Misiewicz-Krzemińska I., Skupińska K., Graczyk A. et al.: Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells. Biotech. Histochem., 2009; 84; 1; 17-23.
15. Mroz P., Yaroslavsky A., Kharkwal G.B. et al.: Cell death pathways in photodynamic therapy of cancer. Cancer, 2011; 3; 2516-2539.
16. Nevrelova P., Kolarova H., Bajgar R. et al.: Measurement of reactive oxygen species after photodynamic therapy in vitro. Scr. Med. (Brno), 2005; 78; 5; 281-290.
17. Nowis D., Makowski M., Stokłosa T. et al.: Direct tumor damage mechanisms of photodynamic therapy. Acta. Biochim. Pol., 2005; 52; 2; 339-352.
18. Plaetzer K., Krammer B., Berlanda J. et al.: Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci., 2009; 24; 259-268.
19. Pruthi S., Boughey J.C., Brandt K.R. et al.: A multidisciplinary approach to the management of breast cancer. Part 2: Therapeutic considerations. Mayo. Clin. Proc., 2007; 82; 9; 1131-1140.
20. Robertson C.A., Hawkins Evans D., Abrahamse H.: Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B., 2009; 96; 1-8.
21. Saczko J., Chwiłkowska A., Kulbacka J. et al.: Photooxidative action in cancer and normal cells induced by the use of Photofrin® in photodynamic therapy. Folia Biol. (Praha), 2008; 54; 24-29.
22. Teiten M.H., Even P., Burgos P. et al.: Specific fluorescent tracers. Imaging and applications for photodynamic therapy. C.R. Biologies, 2002; 325; 487-493.
23. Triesscheijn M., Baas P., Schellens J.H.M. et al.: Photodynamic therapy in oncology. The Oncologist, 2006; 11; 1034-1044.
24. Tsai T., Hong R.L., Tsai J.Ch. et al.: Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR Cells. Lasers Surg. Med., 2004; 34; 62-72.
25. Weigelt B., Peterse J.L., van't Veer L.J.: Breast cancer metastasis: markers and models. Nature, 2005; 5; 591-602.
26. Wyld L., Reed M.W.R., Brown N.J.: Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br. J. Cancer, 2001; 84; 10; 1384-1386.
27. Xue L., Chiu S., Oleinick N.L.: Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene, 2001; 20; 3420-3427.
28. Xue L., Chiu S., Fiebig A. et al.: Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene, 2003; 22; 9197-9204.
29. Zimmermann A., Walt H., Haller U. et al.: Effects of chlorine-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient. Cancer Chemother. Pharmacol., 2003; 51; 147-154.